Serum activity of chitotriosidase, lysozyme and cathepsin H in patients with lung cancer and patients with inflammatory exudate (preliminary report);Aktywność chitotriozydazy oraz lizozymu i katepsyny H w surowicy chorych na raka płuca i chorych z wysiȩkiem zapalnym (doniesienie wstȩpne)

Polski Merkuriusz Lekarski

Volumn 26, Issue 153, 2009, Pages 194-197

  Golab K ^a,b   Passowicz Muszynska E ^a   Jankowska, R ^a   Warwas, M ^a  

^a UNIVERSITY OF WROC AW   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Cathepsin H; Chitotriosidase; Lung cancer; Lysozome

Indexed keywords

BETA N ACETYLHEXOSAMINIDASE; CATHEPSIN; CATHEPSIN H; CHITOTRIOSIDASE; CYSTEINE PROTEINASE; LYSOZYME; TUMOR MARKER;

AGED; ARTICLE; BLOOD; DIFFERENTIAL DIAGNOSIS; ENZYMOLOGY; FEMALE; HUMAN; LUNG TUMOR; MALE; PLEURA EFFUSION; PLEURISY;

AGED; CATHEPSINS; CYSTEINE ENDOPEPTIDASES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEXOSAMINIDASES; HUMANS; LUNG NEOPLASMS; MALE; MURAMIDASE; PLEURAL EFFUSION; PLEURAL EFFUSION, MALIGNANT; PLEURISY; TUMOR MARKERS, BIOLOGICAL;

EID: 64549089594     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Alberts W.M. (ed.): Diagnosis and Management of lung cancer: ACCP evidence based clinical practice guidelines. Chest, 2007, 132, suppl., 1-422.
2. Bargagli E., Maggiorelli C., Rottoli P.: Human chitotriosidase: a potential new marker of sarcoidosis severity. Respiration, 2008, 76, 234-238.
3. Barrett A.J.: Fluorimetric assays of cathepsin B and cathepsin H with methylcoumarylamide substrates. Biochem. J., 1980, 187, 909-912.
4. Berdowska I.: Cysteine proteases as disease markers. Clin. Chim. Acta., 2004, 342, 41-69.
5. Ginsburg I.: The role of bacteriolysis in the pathophysiology of inflammation, infection and post-infectious sequelae. APMIS, 2002, 110, 753-770.
6. Gołecki M.: Postepy w terapii celowanej niedrobnokomó rkowego raka płuc. Adv. Clin. Exp. Med., 2006, 15, 1107-1112.
7. Hall A.J., Morroll S., Tighe P. i wsp.: Human chitotriosidase is expressed in the eye and lacrimal gland and has an antimicrobial spectrum different from lysozyme. Microbes. Infect., 2008, 10, 69-78.
8. Hollak C.E.M., Van Weely S., Van Oers M.H.J. i wsp.: Marked elevation of plasma chitotriosidase activity, a novel hallmark of Gaucher disease. J. Clin. Invest., 1994, 93, 1288-1292.
9. Johansen J.S., Jensen B.V., Roslind A. i wsp.: Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol. Biomarkers Prev., 2006, 15, 194-202.
10. Jones J.W., Jones M.B., Heniford B.T. i wsp.: Serum lysozyme activity can differentiate infection from rejection in organ transplant recipients. J. Surg. Res., 1999, 84, 134-137.
11. Karadag B., Kucur M., Isman F.K., i wsp.: Serum chitotriosidase activity in patients with coronary artery disease. Circ. J., 2008, 72, 71-75.
12. Kimura M., Tani K., Miyata J. i wsp.: The significance of cathepsins, thrombin and aminopeptidase in diffuse interstitial lung diseases. J. Med. Invest., 2005, 52, 93-100.
13. Kosacka M, Jankowska R.: Epidemiologia raka płuc. Pneumol. Alergol. Pol., 2007, 75, 76-80.
14. Kucur M., Isman F.K., Balc C. i wsp.: Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia. Urologic Oncol. Seminars Orig. Invest, 2008, 26, 47-52.
15. Levy O.: Antibiotic proteins of polymorphonuclear leukocytes. Eur. J. Haematol., 1996, 56, 263-277.
16. Maire I., Guffon N., Froissart R.: Current development and usefulness of biomarkers for Gaucher disease follow up. Rev. Med. Interne., 2007, 28, suppl. 2, 187-192.
17. Malaguarnera L: Chitotriosidase: the yin and yang. Cell. Mol. Life. Sci., 2006, 63, 3018-3029.
18. Oguma K., Oshima H., Aoki M. i wsp.: Activated macrophages promote Wnt signalling through tumour necrosis factor-α in gastric tumour cells. EMBO J., 2008, 27, 1671-1681.
19. Prokopowicz J., Kemona H., Wysocka J. i wsp.: Serum lysozyme activity in patients with lung carcinoma subjected to radiotherapy. Neoplasma, 1985, 32, 605-611.
20. Schweiger A., Staib A., Werle B. i wsp.: Cysteine proteinase cathepsin H in tumours and sera of lung cancer patients.: relation to prognosis and cigarette smoking. Br. J. Cancer, 2000, 82, 782-788.
21. Van Eijk M., Scheij S.S., van Roomen C.P. i wsp.: TLR- and NOD2-de-pendent regulation of human phagocyte-specific chitotriosidase. FEBS Lett., 2007, 581, 5389-5395.
22. Van Ginderachter J.A., Movahedi K., Van den Bossche J. i wsp.: Macrophages, PPARs and cancer. PPAR Res., 2008, 2008, 1-11.
23. Werle B., Schanzenbacher U., Lah T.T. i wsp.: Cystatins in non-small cell lung cancer: tissue levels, localization and relation to prognosis. Oncol. Rep., 2006, 16, 647-655.
24. Zhang X, Mosser D.M.: Macrophage activation by endogenous danger signals. J. Pathol., 2008, 214, 161-178.